type full_text Care Plan TCU HPB Dr [REDACTED] [REDACTED] [REDACTED][REDACTED] FBC OA Clinical Summary [REDACTED] [REDACTED] [REDACTED][REDACTED] [REDACTED_PASSPORT] 95 year old Chinese female DA: indometacin, NSAIDs, Ticlopidine ADL independent, Home ambulant with quad stick, Community ambulant on wheelchair PMHx 1) CCF with multiple admissions for fluid overload ppt by noncompliance to FR, URTI etc Sep 2019 2 DE: EF 55 mild RWMA. Normal LV filling pressure. Mild mod MR 2) AF (CHADSVASC 5) Initiated on apixaban and bisoprolol Sept 2019 Rixaroxaban discontinued during 4/11/19 adm to SKH after pt fell Cx L sided cheek hematoma 3) DM/HTN/HLD 4) Mild moderate Alzheimer's Disease 5) Previous R TKR 6) Spinal stenosis 7) Post vitreous haemorrhage of L eye 8) History of symptomatic Hyperthyroidism Chronic meds Entresto 100 mg BDApixaban 2.5 mg BDCaCO 3/Vit D 2 tab OM Colecalciferol 1000 U OM Ferrous gluconate 1 cap OM Furosemide 20 mg OM PRNGTN 0.5 mg sublingual PRNIsosoride Mononitrate 60 mg ON Linagliptin 5 mg OM Omepraole 20 mg BDKCL 600 mg OM PRNSimvastatin 20 mg ONAmlodipine 5 mg OMBisoprolol 2.5 mg BDLactulose HOPC 1. Epigastric discomfort x 2 days a/w constipation, nausea nil vomiting 2. Suprapubic pain with dysuria 3. baseline episodic extertional dyspnea a/w bilateral LL edema nil SOB, chest pain currently nil palpitations On examination Vitals T 37.2 HR 71 BP 125/50 SpO2 95 O/ealert lower abdo discomfort nil hernia nil guarding noted mucoid blood stained stools DRE blood stained brown stools, nil melena, masses Initial Investigations FBC Hb 11.3 TW 20.45 Plt 197 NT proBNP 2383 Trop 41 RP U 11.7 Na 139 K 4.2 HCO3 19.4 Cr 116 UFEMELipase, LFT NADProgress in EDIV omeprazole IV roc/flagylIV paracetIV ondanFleet enema Issues Progress 1. Descending colitis CTAP report: Mild short segment fat stranding seen around the descending colon likely represents acute inflammatory change (i.e. Colitis). No drainable collection is seen. 2. Likely liver cirrhosis CT AP: Slightly irregular contour of the liver with left lobe hypertrophy, underlying chronic liver parenchymal changes is not excluded. Patient discharged stable and well on 29/9/21. Med changes Apixaban suspended until next TCU> Dr [REDACTED] [REDACTED] [REDACTED][REDACTED] On discharge TCU HPB Dr [REDACTED] [REDACTED] [REDACTED][REDACTED] FBC OA